Confidential reports of the American Government seem to suggest that GlaxoSmithKline Plc.'s diabetes drug Avandia should be pulled back from the market as it can end up hurting the heart, as has been speculated by some sources.

The findings reportedly stress that if all diabetes patients who are currently on Avandia are instead put on Takeda's Actos medicine, nearly 500 heart attacks and 300 cases of heart failure might just be averted every single month, as Avandia, also marketed as rosiglitazone, can be harmful to the heart.

"Rosiglitazone should be removed from the market", one report, by Dr. David Graham and Dr. Kate Gelperin of the FDA, stressed.

About 2 years ago, sales of Avandia, which was once Glaxo's second highest selling product plunged after an American study, ended up linking it to an increased risk of cardiovascular attacks.

After this study, there were many others which highlighted the same link, but the drug is still marketed, with some experts trying very hard to stop the sales and consumption of Avandia.